The Gozo hospital/medical school and Oxley Capital Group

I have received the email below.

Good morning, Daphne –

Apologies for the length of this email, but it may help to clarify the seemingly inextricable (and convoluted) links between The Russell Group, Queen Mary’s and St Bartholomews (Barts), The Cambridge Industrial Trust, The Oxley Group, Intrasia Capital Oxley RE and the Oxley Capital Group.

The Russell Group is formed of 24 universities. Each one has ‘spin-out’ or technology transfer companies.

Queen Mary’s, the University of London and Barts and the London Trust have joined UCL Partners (UCLP) to create the largest academic health sciences system in the world.

University College London Business PLC (UCLB) is University College London’s (UCL)technology transfer company. It is a wholly owned subsidiary of UCL and is responsible for conducting technology development and commercial transactions for the university.

UCL’s first technology-transfer company was founded in 1989 as UCL Ventures. In February 2001, UCL Ventures, together with the technology-transfer companies of the University of Bristol, the University of Southampton and Imperial College London signed a deal with a £100 million investment fund.

UCL Ventures merged with the Royal Free Hospital’s technology-transfer company, Freemedic plc (founded in 1993) to form UCL Biomedica PLC.

UCL Business PLC (UCLB) was created in August 2006, through the merger of UCL BioMedica with UCL’s internal knowledge transfer department, which is also known as UCL Business.

The former UCL Business had been established to provide a link between UCL’s academics and industry, and to aid the development of commercially valuable technologies arising from UCL research. UCL BioMedica had been established to commercialise opportunities arising from UCL’s biomedical research strengths, as well as to conduct clinical trials.

The integration of the two technology transfer activities created a single organisation which concentrates on taking the process through from patent registration and support for the creation of new businesses, to licensing and sale of technologies to industry partners.

UCLB has an equity stake in spin-out companies which arise from technology developed across the full range of UCL faculties, including biomedical, biotechnology, engineering, mathematics, physical sciences and built-environment companies. They also sell them off.

In January 2011, BioVex, a cancer vaccines company spun-out of UCL in 1999, was sold to Amgen for $1 billion.

Another spin-out, Queen Mary Innovation (QMI), works closely with QMUL. For instance, QMB Innovation Centre, which is on the Whitechapel campus is fully let out and houses pharmaceutical and chemical research companies from across Europe.

Philip Henry Lewis Levinson was appointed chief executive officer/executive director of Cambridge Industrial Trust Management Ltd on 31 March 2014. His published CV says that he has close to 30 years of regional experience, including 10 years in Singapore, in real estate investments, fund management, business development and private equity.

Before joining CITM, Levinson ran Blackstone’s third-party private placement business, Park Hill Real Estate Asia, raising real estate investment capital from pension and sovereign funds throughout the Asia Pacific region. Before that, he set up Blackstone’s Australia operations in 2009, after having run regional investor relations and business development businesses for Deutsche Asset Management and LaSalle Investment Management.

Cambridge Industrial Trust is owned by three shareholders: The National Australian Bank (NAB), Oxley Group and Mitsubishi & Co. Michael Dwyer is executive chairman of Oxley Capital Group, based in Singapore. He is also executive director of Cambridge Industrial Trust Management.